Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel acquired 6,000 shares of the company’s stock in a transaction dated Tuesday, June 7th. The shares were bought at an average cost of $8.55 per share, for a total transaction of $51,300.00. Following the completion of the acquisition, the chief executive officer now directly owns […]
Greenwich LifeSciences (NASDAQ:GLSI – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Monday, Zacks.com reports. According to Zacks, “Greenwich LifeSciences Inc. is a clinical stage biopharmaceutical company focuses on the development of cancer immunotherapies for breast cancer and other human epidermal growth […]
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel acquired 6,000 shares of the stock in a transaction that occurred on Thursday, April 21st. The stock was purchased at an average price of $16.09 per share, with a total value of $96,540.00. Following the completion of the transaction, the chief executive officer now owns […]
Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Rating) CEO Snehal Patel bought 6,000 shares of the stock in a transaction that occurred on Tuesday, April 19th. The shares were bought at an average price of $16.74 per share, for a total transaction of $100,440.00. Following the completion of the transaction, the chief executive officer now directly […]